CD274 and renal cell carcinoma: After pembrolizumab monotherapy for ≥1% PD-L1 expressing NSCLC, 67% of the patients (n = 27) progressed in the CNS within 1 year.9 In RCC, Flippot et al. observed that 72% of the patients needed focal brain therapy (36% SRS, 23% WBRT ± SRS, 13% surgery ± SRS) following nivolumab.